Bio-Techne Corp
TECH65.850USD
+2.360+3.72%
Handelsschluss 11/25, 16:00（ET）Kurse um 15 Minuten verzögert
10.26BMarktkapitalisierung
131.57KGV TTM
mehr Informationen über Bio-Techne Corp Unternehmen
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Bio-Techne Corp Informationen
BörsenkürzelTECH
Name des UnternehmensBio-Techne Corp
IPO-datumFeb 09, 1989
CEOMr. Kim Kelderman
Anzahl der mitarbeiter3100
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 09
Addresse614 Mckinley Pl N E
StadtMINNEAPOLIS
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl55413
Telefon16123792956
Websitehttps://www.bio-techne.com/
BörsenkürzelTECH
IPO-datumFeb 09, 1989
CEOMr. Kim Kelderman
Führungskräfte von Bio-Techne Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+2.51%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-4.52%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+3.66%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+11.91%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+17.55%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+22.99%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Spatial Biology
President - Diagnostics and Spatial Biology
4.74K
+169.49%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
4.38K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
3.78K
+76.56%
Mr. James T. (Jim) Hippel
Mr. James T. (Jim) Hippel
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+2.51%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-4.52%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+3.66%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+11.91%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+17.55%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+22.99%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables
972.29M
79.72%
Instruments
112.09M
9.19%
Service
111.57M
9.15%
Royalty
23.69M
1.94%
Nach RegionUSD
Name
Umsatz
Anteil
United States
683.23M
56.02%
EMEA, excluding U.K
266.31M
21.83%
Greater China
100.46M
8.24%
APAC, excluding Greater China
77.26M
6.33%
United Kingdom
54.83M
4.50%
Rest of World
37.55M
3.08%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables
972.29M
79.72%
Instruments
112.09M
9.19%
Service
111.57M
9.15%
Royalty
23.69M
1.94%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Andere
72.73%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Andere
72.73%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
57.86%
Investment Advisor/Hedge Fund
34.00%
Hedge Fund
8.05%
Bank and Trust
2.18%
Research Firm
1.96%
Pension Fund
1.33%
Sovereign Wealth Fund
1.24%
Individual Investor
0.28%
Insurance Company
0.24%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
1198
161.18M
103.53%
-7.34M
2025Q2
1209
165.25M
105.41%
-730.33K
2025Q1
1245
168.10M
107.22%
+1.54M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
18.40M
11.82%
-60.83K
-0.33%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.79M
5.65%
-512.26K
-5.50%
Jun 30, 2025
State Street Investment Management (US)
5.86M
3.76%
-671.30K
-10.28%
Jun 30, 2025
Atlanta Capital Management Company, L.L.C.
4.29M
2.76%
+573.23K
+15.41%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.06M
2.61%
-30.89K
-0.75%
Jun 30, 2025
Invesco Capital Management LLC
3.24M
2.08%
+274.96K
+9.28%
Jun 30, 2025
Neuberger Berman, LLC
2.50M
1.61%
-526.06K
-17.38%
Jun 30, 2025
T. Rowe Price Associates, Inc.
8.62M
5.53%
-2.53M
-22.68%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
Global X Genomics & Biotechnology ETF
3.95%
Invesco Biotechnology & Genome ETF
2.62%
Invesco S&P 500 Equal Weight Health Care ETF
1.79%
VanEck Biotech ETF
1.63%
Neuberger Berman Small-Mid Cap ETF
1.58%
Hilton Small-MidCap Opportunity ETF
1.55%
Thrivent Small-Mid Cap ESG ETF
1.44%
American Century Mid Cap Growth Impact ETF
1.39%
WisdomTree BioRevolution Fund
1.22%
iShares Health Innovation Active ETF
1.2%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil3.95%
Invesco Biotechnology & Genome ETF
Anteil2.62%
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.79%
VanEck Biotech ETF
Anteil1.63%
Neuberger Berman Small-Mid Cap ETF
Anteil1.58%
Hilton Small-MidCap Opportunity ETF
Anteil1.55%
Thrivent Small-Mid Cap ESG ETF
Anteil1.44%
American Century Mid Cap Growth Impact ETF
Anteil1.39%
WisdomTree BioRevolution Fund
Anteil1.22%
iShares Health Innovation Active ETF
Anteil1.2%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
250.90M
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Nov 01, 2022
Split
1→4
Datum
Art
Verhältnis
Nov 01, 2022
Split
1→4
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Bio-Techne Corp?
Die fünf größten Anteilseigner von Bio-Techne Corp sind:
The Vanguard Group, Inc. hält 18.40M Aktien, was 11.82% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 8.79M Aktien, was 5.65% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 5.86M Aktien, was 3.76% der Gesamtaktien entspricht.
Atlanta Capital Management Company, L.L.C. hält 4.29M Aktien, was 2.76% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 4.06M Aktien, was 2.61% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 18.40M Aktien, was 11.82% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 8.79M Aktien, was 5.65% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 5.86M Aktien, was 3.76% der Gesamtaktien entspricht.
Atlanta Capital Management Company, L.L.C. hält 4.29M Aktien, was 2.76% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 4.06M Aktien, was 2.61% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Bio-Techne Corp?
Die drei wichtigsten Anteilseigner-Typen von Bio-Techne Corp sind:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Wie viele Institutionen halten Anteile an Bio-Techne Corp (TECH)?
Mit Stand vom 2025Q3 halten 1198 Institutionen Anteile an Bio-Techne Corp, mit einem Gesamtmarktwert von etwa 161.18M, was 103.53% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um -1.88% gestiegen.
Was ist die größte Einnahmequelle von Bio-Techne Corp?
Am FY2025 erzielte das Geschäft mit Consumables für Bio-Techne Corp den höchsten Umsatz in Höhe von 972.29M, was 79.72% des Gesamtumsatzes entspricht.
